For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the emergence of Vyndamax and Attruby represents a genuine breakthrough . These novel therapies protect the transthyretin protein, slowing its destructive build-up and lessening the severity of the condition . Patients are now seeing positive outcomes i